ASKA Pharmaceutical Holdings Co Ltd (4886:TSE) Stock Forecast
Alert
Its only available to paid users.
N/A
Based on the ASKA Pharmaceutical Holdings Co Ltd stock forecast from 0 analysts, the average analyst target price for ASKA Pharmaceutical Holdings Co Ltd is not available over the next 12 months. ASKA Pharmaceutical Holdings Co Ltd’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of ASKA Pharmaceutical Holdings Co Ltd is Slightly Bullish , which is based on 9 positive signals and 5 negative signals. At the last closing, ASKA Pharmaceutical Holdings Co Ltd’s stock price was JPY 2,059.00. ASKA Pharmaceutical Holdings Co Ltd’s stock price has changed by +0.54% over the past week, +2.39% over the past month and +16.46% over the last year.
No recent analyst target price found for ASKA Pharmaceutical Holdings Co Ltd
No recent average analyst rating found for ASKA Pharmaceutical Holdings Co Ltd
Company Overview ASKA Pharmaceutical Holdings Co Ltd
ASKA Pharmaceutical Holdings Co.,Ltd., through its subsidiaries, engages in the pharmaceutical, animal health, and hormone testing businesses in Japan. The company researches, develops, manufactures, and markets pharmaceutical products in the areas of endocrinology, obstetrics and gynecology, and urology; and researches, manufactures, sells, imports, and exports veterinary medicines, veterinary medical devices, feed and feed additives, reagents, agrochemicals, industrial chemicals, hygiene products, and food products and their raw materials. It is also involved in the clinical examination and biological testing activities; and offers medical devices. ASKA Pharmaceutical Holdings Co.,Ltd. was founded in 1920 and is headquartered in Tokyo, Japan. Read Less
ASKA Pharmaceutical Holdings Co.,Ltd., through its subsidiaries, engages in the pharmaceutical, animal health, and hormone testing businesses in Japan. The company researches, develops, manufactures, and markets pharmaceutical products in the areas of endocrinology, obstetrics an...Read More
Frequently Asked Questions About ASKA Pharmaceutical Holdings Co Ltd (4886:TSE) Stock
Stock Target Advisor's fundamental analysis for ASKA Pharmaceutical Holdings Co Ltd's stock is Slightly Bullish .
4886:TSE stock's dividend yield is 2.36%.
Our analysis grades 4886:TSE stock's dividend yield at F. This means that 4886:TSE stock's dividend yield is above 17% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the TSE exchange.
Based on this 4886:TSE may be a poor dividend stock for its sector.
Unfortunately we do not have enough data on 4886:TSE's stock to indicate what its average analyst target is.
4886:TSE stock's Price/Earning ratio is 9.94.
Our analysis grades 4886:TSE stock's Price / Earning ratio at C. This means that 4886:TSE stock's Price/Earning ratio is above 27% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the TSE exchange.
Based on this 4886:TSE may be undervalued for its sector.
The last closing price of 4886:TSE's stock was JPY 2,059.00.
The most recent market capitalization for 4886:TSE is JPY 59.51B.
Unfortunately we do not have enough analyst data on 4886:TSE's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains ASKA Pharmaceutical Holdings Co Ltd's stock.
As per our most recent records ASKA Pharmaceutical Holdings Co Ltd has 762 Employees.
ASKA Pharmaceutical Holdings Co Ltd's registered address is 5-1, Shibaura 2-Chome, Tokyo, Japan, 108-8532.
You can get more information about it from ASKA Pharmaceutical Holdings Co Ltd's website at https://www.aska-pharma-hd.co.jp.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low debt
The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
What not to like
Below median total returns
The company has under performed its peers on annual average total returns in the past 5 years.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Low Dividend Growth
This stock has shown below median dividend growth in the previous 5 years compared to its sector.
Frequently Asked Questions About ASKA Pharmaceutical Holdings Co Ltd (4886:TSE) Stock
Stock Target Advisor's fundamental analysis for ASKA Pharmaceutical Holdings Co Ltd's stock is Slightly Bullish .
4886:TSE stock's dividend yield is 2.36%.
Our analysis grades 4886:TSE stock's dividend yield at F. This means that 4886:TSE stock's dividend yield is above 17% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the TSE exchange.
Based on this 4886:TSE may be a poor dividend stock for its sector.
Unfortunately we do not have enough data on 4886:TSE's stock to indicate what its average analyst target is.
4886:TSE stock's Price/Earning ratio is 9.94.
Our analysis grades 4886:TSE stock's Price / Earning ratio at C. This means that 4886:TSE stock's Price/Earning ratio is above 27% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the TSE exchange.
Based on this 4886:TSE may be undervalued for its sector.
The last closing price of 4886:TSE's stock was JPY 2,059.00.
The most recent market capitalization for 4886:TSE is JPY 59.51B.
Unfortunately we do not have enough analyst data on 4886:TSE's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains ASKA Pharmaceutical Holdings Co Ltd's stock.
As per our most recent records ASKA Pharmaceutical Holdings Co Ltd has 762 Employees.
ASKA Pharmaceutical Holdings Co Ltd's registered address is 5-1, Shibaura 2-Chome, Tokyo, Japan, 108-8532.
You can get more information about it from ASKA Pharmaceutical Holdings Co Ltd's website at https://www.aska-pharma-hd.co.jp.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for 4886:TSE !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
